心力衰竭药物遗传学：过去、现在和未来。
Heart failure pharmacogenetics: past, present, and future.
机构信息
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
出版信息
Curr Cardiol Rep. 2011 Jun;13(3):175-84. doi: 10.1007/s11886-011-0181-6.
Heart failure is an increasingly common disease associated with significant morbidity and mortality in the aging population. Recent advances in heart failure pharmacotherapy have established several agents as beneficial to disease progression and outcomes. However, current consensus guideline-recommended pharmacotherapy may not represent an optimal treatment strategy in all heart failure patients. Specifically, individuals with genetic variation in regions central to mediation of beneficial response to standard heart failure agents may not receive optimal benefit from these drugs. Additionally, targeted approaches in phase 3 clinical trials that select patients for inclusion based on the genotype most likely to respond might advance the currently stalled drug development pipeline in heart failure. This article reviews the literature in heart failure pharmacogenetics to date, opportunities for discovery in recent and upcoming clinical trials, as well as future directions in this field.
心力衰竭是一种在老年人群中发病率和死亡率都很高的常见疾病。心力衰竭药物治疗的最新进展已经确定了几种对疾病进展和结局有益的药物。然而，目前的共识指南推荐的药物治疗方案可能并不代表所有心力衰竭患者的最佳治疗策略。具体来说，在对标准心力衰竭药物治疗反应起重要调节作用的区域存在遗传变异的个体，可能无法从这些药物中获得最佳疗效。此外，在 3 期临床试验中，基于最有可能产生反应的基因型来选择入组患者的靶向治疗方法，可能会推动心力衰竭药物研发目前停滞不前的进程。本文综述了心力衰竭药物遗传学的现有文献，以及近期和即将开展的临床试验中的发现机会，以及该领域的未来方向。
Zotero 插件